Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,253 | 548 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,937 | 177 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,590 | 89 | $0 (2024) |
| Janssen Biotech, Inc. | $811.76 | 51 | $0 (2024) |
| Gilead Sciences, Inc. | $790.73 | 25 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $609.48 | 34 | $0 (2024) |
| Merck Sharp & Dohme LLC | $332.41 | 20 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $221.23 | 13 | $0 (2022) |
| Daiichi Sankyo Inc. | $201.35 | 6 | $0 (2020) |
| GENZYME CORPORATION | $190.20 | 6 | $0 (2024) |
| Allergan, Inc. | $178.51 | 12 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,719 | 89 | ABBVIE INC. ($568.63) |
| 2023 | $1,940 | 99 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($530.61) |
| 2022 | $1,587 | 89 | ABBVIE INC. ($704.02) |
| 2021 | $1,140 | 66 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($345.36) |
| 2020 | $550.00 | 33 | AbbVie Inc. ($138.99) |
| 2019 | $920.60 | 58 | AbbVie, Inc. ($201.65) |
| 2018 | $1,194 | 68 | AbbVie, Inc. ($310.32) |
| 2017 | $1,202 | 46 | AbbVie, Inc. ($307.17) |
All Payment Transactions
548 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Gastroenterology | ||||||
| 12/16/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: LIVER DISEASE | ||||||
| 12/12/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: Genetic Disease | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.89 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $5.21 | General |
| Category: VIROLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: VIROLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: LIVER DISEASE | ||||||
| 10/29/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $6.60 | General |
| Category: VIROLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $4.67 | General |
| Category: VIROLOGY | ||||||
| 10/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.35 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/07/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.27 | General |
| Category: Neuroscience | ||||||
| 10/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 537 | 611 | $285,737 | $61,544 |
| 2022 | 16 | 552 | 638 | $293,748 | $58,753 |
| 2021 | 12 | 571 | 701 | $292,756 | $64,950 |
| 2020 | 16 | 692 | 837 | $316,342 | $72,221 |
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 60 | 60 | $56,882 | $11,721 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 83 | 108 | $42,336 | $9,963 | 23.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 77 | $15,216 | $4,638 | 30.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 34 | 34 | $27,346 | $4,540 | 16.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 49 | 51 | $30,602 | $4,514 | 14.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 26 | 26 | $19,422 | $4,507 | 23.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 40 | $14,493 | $3,965 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 61 | 65 | $17,940 | $3,655 | 20.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $16,731 | $3,340 | 20.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 15 | 15 | $11,205 | $2,605 | 23.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $10,359 | $2,377 | 22.9% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 22 | 22 | $9,741 | $1,931 | 19.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 17 | $4,617 | $1,450 | 31.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $6,780 | $1,390 | 20.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 18 | 25 | $2,067 | $948.25 | 45.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 48 | 48 | $45,264 | $9,366 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 74 | 95 | $37,240 | $7,607 | 20.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 58 | 112 | $23,219 | $5,995 | 25.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 62 | 65 | $39,000 | $5,505 | 14.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 53 | 53 | $20,913 | $5,374 | 25.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $28,392 | $4,692 | 16.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 50 | $13,800 | $3,207 | 23.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 31 | 31 | $24,583 | $2,933 | 11.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $9,232 | $2,571 | 27.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 14 | 15 | $11,205 | $2,557 | 22.8% |
About Dr. Brent Acker, MD
Dr. Brent Acker, MD is a Internal Medicine healthcare provider based in Savannah, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/30/2011. The National Provider Identifier (NPI) number assigned to this provider is 1407147028.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brent Acker, MD has received a total of $10,253 in payments from pharmaceutical and medical device companies, with $1,719 received in 2024. These payments were reported across 548 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($10,253).
As a Medicare-enrolled provider, Acker has provided services to 2,352 Medicare beneficiaries, totaling 2,787 services with total Medicare billing of $257,468. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Gastroenterology
- Location Savannah, GA
- Active Since 04/30/2011
- Last Updated 08/17/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1407147028
Products in Payments
- XIFAXAN (Drug) $1,091
- RINVOQ (Biological) $845.64
- STELARA (Biological) $510.18
- HUMIRA (Biological) $461.31
- TRULANCE (Drug) $433.96
- Humira (Biological) $366.51
- Entyvio (Biological) $331.92
- DIFICID (Drug) $318.89
- MAVYRET (Drug) $305.25
- REMICADE (Biological) $304.48
- DUPIXENT (Biological) $301.39
- LINZESS (Drug) $234.00
- Viekira (Drug) $220.56
- Vemlidy (Drug) $220.53
- Linzess (Drug) $203.28
- INJECTAFER (Drug) $201.35
- ENTYVIO (Biological) $173.95
- SKYRIZI (Biological) $167.84
- VIBERZI (Drug) $158.90
- GATTEX (Drug) $149.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Savannah
Dr. Jennifer Woehler, D.o, D.O
Internal Medicine — Payments: $183,589
Dr. Michael Perkins, M.d, M.D
Internal Medicine — Payments: $68,118
Paul Bradley, Md, MD
Internal Medicine — Payments: $33,506
John Demicco, M.d, M.D
Internal Medicine — Payments: $32,210
Dr. Timothy Connelly, Md, MD
Internal Medicine — Payments: $24,711
Wilfredo Dolor, Md, MD
Internal Medicine — Payments: $20,320